Patents by Inventor Edward P. Amento

Edward P. Amento has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9534034
    Abstract: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject.
    Type: Grant
    Filed: February 17, 2012
    Date of Patent: January 3, 2017
    Assignee: Molecular Medicine Research Institute
    Inventors: Edward P. Amento, Chrishan S. Samuel
  • Publication number: 20120238499
    Abstract: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject.
    Type: Application
    Filed: February 17, 2012
    Publication date: September 20, 2012
    Applicant: MOLECULAR MEDICINE RESEARCH INSTITUTE
    Inventors: Edward P. Amento, Chrishan S. Samuel
  • Patent number: 8119136
    Abstract: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: February 21, 2012
    Assignee: Molecular Medicine Research Institute
    Inventors: Edward P. Amento, Christian S. Samuel
  • Publication number: 20110059108
    Abstract: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject.
    Type: Application
    Filed: November 12, 2010
    Publication date: March 10, 2011
    Applicant: MOLECULAR MEDICINE RESEARCH INSTITUTE
    Inventors: Edward P. Amento, Chrishan S. Samuel
  • Patent number: 7833526
    Abstract: The present invention relates to the discovery that relaxin is associated with the development or maturation of body tissues. Knockouts of the gene encoding relaxin result in various abnormalities in the development of various tissues. The present invention provides methods of modulating apoptosis by administering a relaxin agonist or antagonist to a subject.
    Type: Grant
    Filed: July 23, 2007
    Date of Patent: November 16, 2010
    Assignee: Molecular Medicine Research Institute
    Inventors: Edward P. Amento, Chrishan S. Samuel
  • Publication number: 20040081635
    Abstract: The use of low doses of IFN-gamma in the treatment of interferon-sensitive diseases is described. The IFN-gamma can be administered orally, preferably buccally or sublingually, or parenterally in low doses to activate monocyte, neutrophil, or B cell function, to decrease acute inflammation, or to treat cancer, bacterial or fungal diseases, or fibrosis in a patient suffering from such disease states. Pharmaceutical formulations containing low doses of IFN-gamma in combination with a pharmaceutical acceptable carrier and suitable for oral administration are also described.
    Type: Application
    Filed: October 22, 2003
    Publication date: April 29, 2004
    Inventors: Joseph M. Cummins, Edward P. Amento
  • Patent number: 5753623
    Abstract: Depression, particularly disease- and medical treatment-related depression, and especially postpartum depression, is treated by the administration of a therapeutically effective amount of relaxin. A treatment regimen and dosage form for gradual withdrawal from relaxin therapy is also disclosed.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: May 19, 1998
    Assignee: Connetics Corporation
    Inventors: Edward P. Amento, Eugene A. Bauer
  • Patent number: 5108989
    Abstract: A method of predisposing a mammal to accelerated tissue repair is provided. This method comprises systemically administering to the mammal, prior to its exposure to tissue damage, an effective amount of TGF-.beta.. Preferably, the TGF-.beta. is administered no more than about 24 hours prior to exposure to tissue damage.
    Type: Grant
    Filed: April 4, 1990
    Date of Patent: April 28, 1992
    Assignee: Genentech, Inc.
    Inventors: Edward P. Amento, L. Steven Beck